Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients

Journal of Substance Abuse Treatment

Volumn 46, Issue 4, 2014, Pages 456-462

  Tkacz, Joseph ^a   Volpicelli, Joseph ^b   Un, Hyong ^c   Ruetsch, Charles ^a  

^a Health Analytics LLC   (United States)

^b Institute of Addiction Medicine   (United States)

^c AETNA   (United States)

Author keywords

Adherence; Buprenorphine; Dependence; Opiate; Opioid; Pharmacoeconomics

Indexed keywords

ADHERENCE; BUPRENORPHINE; DEPENDENCE; OPIATE; OPIOID; PHARMACOECONOMICS;

ADULT; BUPRENORPHINE; DATABASES, FACTUAL; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; LINEAR MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OPIOID-RELATED DISORDERS; YOUNG ADULT;

EID: 84894267016     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2013.10.014     Document Type: Article

References (41)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revised 2000, American Psychiatric Association, Washington, DC.
2. Barnett P.G. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009, 104:982-992.
3. Bertakis K.D., Azari R., Helms L.J., Callahan E.J., Robbins J.A. Gender differences in the utilization of health care services. Journal of Family Practice 2000, 49:147-152.
4. Birnbaum H.G., White A.G., Schiller M., Waldman T., Cleveland J.M., Roland C.L. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Medicine 2011, 12:657-667.
5. Bosworth H.B., The National Consumers League Medication adherence: Making the case for increased awareness 2011, Duke University Medical Center.
6. Center for Health Program Development and Management Review of cost-benefit and cost-effectiveness literature for methadone or buprenorphine as a treatment for opiate addiction 2007, University of Maryland, Baltimore County, Baltimore, MD.
7. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases 1987, 40:373-383.
8. Cooper J., Hall L., Penland A., Krueger A., May J. Measuring medication adherence. Population Health Management 2009, 12:25-30.
9. Dalton K., Freeman S., Bragg A. Refining cost to charge ratios for calculating APC and DRG relative payment weights 2008, RTI International, Research Triangle Park, NC.
10. DiMatteo M.R., Giordani P.J., Lepper H.S., Croghan T.W. Patient adherence and medical treatment outcomes: A meta-analysis. Medical Care 2002, 40:794-811.
11. Doran C.M. Economic evaluation of interventions to treat opiate dependence: A review of the evidence. PharmacoEconomics 2008, 26:371-393.
12. Finkler S.A. The distinction between cost and charges. Annals of Internal Medicine 1982, 96:102-109.
13. Fischer B., Gittins J., Rehm J. Characterizing the "awakening elephant" of prescription opioid misuse in North America: Epidemiology, harms, interventions. Contemporary Drug Problems 2008, 35:397-426.
14. Healthcare Cost and Utilization Project Cost-to-charge ratio files Retrieved July 18th, 2013, from. http://www.hcup-us.ahrq.gov/db/state/costtocharge.jsp.
15. Johnson R.E., McCagh J.C. Buprenorphine and naloxone for heroin dependence. Current Psychiatry Reports 2000, 2:519-526.
16. Laakso L.J. Motivational interviewing: Addressing ambivalence to improve medication adherence in patients with bipolar disorder. Issues in Mental Health Nursing 2012, 33:8-14.
17. Lee W.C., Balu S., Cobden D., Joshi A.V., Pashos C.L. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data. Clinical Therapeutics 2006, 28:1712-1725. (discussion 1710-1711).
18. Ling W., Casadonte P., Bigelow G., Kampman K.M., Patkar A., Bailey G.L., et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA 2010, 304:1576-1583.
19. Manchikanti L., Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 2008, 11(2 Suppl):S63-S88.
20. McCance-Katz E.F. Office-based buprenorphine treatment for opioid-dependent patients. Harvard Review of Psychiatry 2004, 12:321-338.
21. McCollister K.E., French M.T. The relative contribution of outcome domains in the total economic benefit of addiction interventions: A review of first findings. Addiction 2003, 98:1647-1659.
22. Moorin R., Gibson D., Holman D., Hendrie D. The contribution of age and time-to-death on health care expenditure for out-of-hospital services. Journal of Health Services Research & Policy 2012, 17:197-205.
23. Nomof N. Cost vs charge. American Journal of Cardiology 1995, 75(16):1187.
24. Peterson A.M., Nau D.P., Cramer J.A., Benner J., Gwadry-Sridhar F., Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value in Health 2007, 10:3-12.
25. Polsky D., Glick H.A., Yang J., Subramaniam G.A., Poole S.A., Woody G.E. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: Data from a randomized trial. Addiction 2010, 105:1616-1624.
26. Roebuck M.C., Liberman J.N., Gemmill-Toyama M., Brennan T.A. Medication adherence leads to lower health care use and costs despite increased drug spending. Health affairs (Project Hope) 2011, 30:91-99.
27. Ruetsch C., Tkacz J., McPherson T.L., Cacciola J. The effect of telephonic patient support on treatment for opioid dependence: Outcomes at one year follow-up. Addictive Behaviors 2012, 37:686-689.
28. Ruppar T.M. Randomized pilot study of a behavioral feedback intervention to improve medication adherence in older adults with hypertension. Journal of Cardiovascular Nursing 2010, 25:470-479.
29. Salas M., Hughes D., Zuluaga A., Vardeva K., Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: A systematic review and critical analysis of the literature. Value in Health 2009, 12:915-922.
30. Schackman B.R., Leff J.A., Polsky D., Moore B.A., Fiellin D.A. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. Journal of General Internal Medicine 2012, 27:669-676.
31. Sokol M.C., McGuigan K.A., Verbrugge R.R., Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care 2005, 43:521-530.
32. Substance Abuse And Mental Health Service Administration Results from the 2002 National Survey on Drug Use and Health: National Findings 2003.
33. Substance Abuse and Mental Health Service Administration Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction 2004.
34. Tkacz J., Severt J., Cacciola J., Ruetsch C. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. American Journal on Addictions 2012, 21:55-62.
35. Tkacz J., Severt J., Kassed C., Ruetsch C. Clinical differences between opioid abuse classes ameliorated after 1year of buprenorphine-medication assisted treatment. Journal of Addictive Diseases 2012, 31:100-111.
36. Tyree P.T., Lind B.K., Lafferty W.E. Challenges of using medical insurance claims data for utilization analysis. American Journal of Medical Quality 2006, 21:269-275.
37. Vervloet M., Linn A.J., van Weert J.C., de Bakker D.H., Bouvy M.L., van Dijk L. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: A systematic review of the literature. Journal of the American Medical Informatics Association 2012, 19:696-704.
38. Warden D., Subramaniam G.A., Carmody T., Woody G.E., Minhajuddin A., Poole S.A., et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addictive Behaviors 2012, 37:1046-1053.
39. Watanabe J.H., Bounthavong M., Chen T. Revisiting the medication possession ratio threshold for adherence in lipid management. Current Medical Research and Opinion 2013, 29:175-180.
40. White A.G., Birnbaum H.G., Mareva M.N., Daher M., Vallow S., Schein J., et al. Direct costs of opioid abuse in an insured population in the United States. Journal of Managed Care Pharmacy 2005, 11:469-479.
41. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., Sannerud C. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug and Alcohol Dependence 2003, 69:215-232.